Publicaciones en colaboración con investigadores/as de Columbia University (20)

2024

  1. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2022

  1. Guiding the global evolution of cytogenetic testing for hematologic malignancies

    Blood, Vol. 139, Núm. 15, pp. 2273-2284

2021

  1. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507

  2. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  3. The Risk of Contracting COVID-19 Is Not Increased in Patients With Celiac Disease

    Clinical Gastroenterology and Hepatology

  4. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130

  5. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

  6. Worldwide Survey of COVID-19-Associated Arrhythmias

    Circulation: Arrhythmia and Electrophysiology, Vol. 14, Núm. 3, pp. E009458

2020

  1. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

2019

  1. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312

2018

  1. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR

    Haematologica, Vol. 103, Núm. 12, pp. 2079-2087

2016

  1. Heterogeneity of psychosis risk within individuals at clinical high risk: A meta-analytical stratification

    JAMA Psychiatry, Vol. 73, Núm. 2, pp. 113-120

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346

2015

  1. A global reference for human genetic variation

    Nature, Vol. 526, Núm. 7571, pp. 68-74

  2. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

2014

  1. Distinction between asymptomatic monoclonal b-cell lymphocytosis with cyclin d1 overexpression and mantle cell lymphoma: From molecular profiling to flow cytometry

    Clinical Cancer Research, Vol. 20, Núm. 4, pp. 1007-1019

2013

  1. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease

    Journal of Clinical Oncology, Vol. 31, Núm. 18, pp. 2347-2357

2009

  1. International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review

    Leukemia, Vol. 23, Núm. 12, pp. 2210-2221

2006

  1. Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

    Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383